Introduction
============

An essential amino acid, tryptophan (Trp), is known to be metabolized to several neuroactive substances such as serotonin, kynurenic acid, and quinolinic acid. Analyses of Trp and its metabolites in biological fluids, such as serum or plasma, are of clinical importance for diagnosis of several diseases in humans as several reports have indicated that concentrations of Trp and its metabolites are altered in various disease states.[@b1-ijtr-suppl.1-2013-009]--[@b5-ijtr-suppl.1-2013-009] Tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3-dioxygenase (IDO) can metabolize Trp to *N*-formyl-[l]{.smallcaps}-kynurenine (KYN).[@b6-ijtr-suppl.1-2013-009]--[@b11-ijtr-suppl.1-2013-009] KYN is also produced non-enzymatically by deformylation of *N*-formyl- KYN because of the instability of the latter compound. Changes in the expression and activity of IDO have been found to be associated with intractable diseases, including cancer, amyotrophic lateral sclerosis, multiple sclerosis.[@b7-ijtr-suppl.1-2013-009],[@b9-ijtr-suppl.1-2013-009],[@b11-ijtr-suppl.1-2013-009]

Thus far, the expression levels of IDO and TDO in cell culture or tissues of experimental rodents has been mainly investigated by western blot (WB) analysis.[@b8-ijtr-suppl.1-2013-009],[@b10-ijtr-suppl.1-2013-009] However, precise quantitation of the expressed enzyme by WB analysis is difficult, although the expression of TDO and IDO can be separately analyzed. Therefore, to monitor both IDO and TDO activity simultaneously requires an alternative way of measuring the concentrations of the substrate and the product, [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN, respectively. Such methodology would make it possible to assess IDO and TDO activity in vivo, because blood or urine samples can be easily obtained from human subjects or experimental animals. To date, several HPLC methods that enable determination of [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN simultaneously by using UV,[@b12-ijtr-suppl.1-2013-009] fluorescence,[@b13-ijtr-suppl.1-2013-009] electrochemical,[@b14-ijtr-suppl.1-2013-009] or mass spectrometric (MS) detection,[@b15-ijtr-suppl.1-2013-009],[@b16-ijtr-suppl.1-2013-009] have been reported.

In this study, we developed a method employing HPLC with MS detection for simultaneous determination of [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations, by modification of our previous HPLC method[@b17-ijtr-suppl.1-2013-009] with pre-column derivatization with a fluorescence reagent, (*R*)-(−)-4-(*N*, *N*-dimethylaminosulfonyl)-7- (3-isothiocyanatopyrrolidin-1-yl)-2,1,3-benzoxadiazole (DBD-PyNCS).[@b18-ijtr-suppl.1-2013-009] Using the HPLC-MS method proposed in this study, [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in human serum can be determined using 10 μL of serum.

Materials and Methods
=====================

Chemicals
---------

[l]{.smallcaps}-Trp was obtained from Nacalai Tesque Inc. (Kyoto, Japan). (*R*)*-*(−)-DBD-PyNCS, 4-*N*, *N*-dimethylaminopyridine (DMAP), and 7-aminoheptanoic acid were purchased from Tokyo Kasei Co., Ltd. (Tokyo, Japan). Acetic acid (AcOH) of HPLC grade was obtained from Wako Pure Chemical Industries Ltd. (Osaka, Japan). [l]{.smallcaps}-KYN was obtained from Sigma-Aldrich (St. Louis, MO, USA). Acetonitrile (CH~3~CN) of HPLC grade was obtained from Kanto Kagaku Co., Ltd. (Tokyo, Japan). Millipore-purified (Nihon Millipore K.K., Tokyo, Japan) water was used in all experiments.

Serum samples from human volunteers
-----------------------------------

Healthy human volunteers (n = 19; 8 men and 11 women) participated in this study; the mean age was 23.6 ± 3.5 y (mean ± SD). Written informed consent was obtained from all subjects prior to their participation in this study, and the protocol was approved by the Ethics Committee of Toho University, Faculty of Pharmaceutical Sciences.

Five milliliters of blood was drawn from the arm vein of participants between 11:00--12:00 am, before lunch, and was collected in Venoject-II^®^ AUTOSEP tubes (Terumo Corporation, Tokyo, Japan) for 30 min at room temperature. The tubes were then centrifuged at 1,200 × g for 15 min. The serum obtained was divided into aliquots of 100 μL each into screw-capped vials, which were stored at −80 °C.

Determination of [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN in human serum
---------------------------------------------------------------------------

[l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in human serum samples were simultaneously determined by an HPLC-electrospray ionization (ESI)-MS method (LC-MS), in which the detection system in our previously described HPLC method[@b17-ijtr-suppl.1-2013-009] was changed from a fluorescence to an MS detector. Briefly, 10 μL of serum was mixed vigorously with 10 μL of CH~3~CN/H~2~O (50:50), 10 μL of a 50 μM (for [l]{.smallcaps}-Trp), or 2.5-μM (for [l]{.smallcaps}-KYN) solution of the internal standard (I.S.), 7-aminoheptanoic acid, in CH~3~CN/H~2~O (50:50), and 120 μL of CH~3~CN. These samples were centrifuged at 1,300 × g for 20 min at 4 °C. Ten microliters of the obtained supernatant was sampled and added to 10 μL of a 10-mM solution of (*R*)-(−)-DBD-Py-NCS in CH~3~CN and 10 μL of a 30 mM solution of DMAP in CH~3~CN. The resulting solution was heated at a temperature of 55 °C for 20 min, and then 70 μL of a H~2~O/CH~3~CN (80:20) mixture containing 0.1% AcOH was added to dilute the reacted solution. Thereafter, 50 μL of the final solution was injected onto the LC-MS apparatus, comprising an Agilent 1200series HPLC system (Agilent Technologies, Santa Clara, CA, U.S.A.) and a time-of-flight (TOF)-MS (JMS-T100 LP AccuTOF LC-Plus) equipped with an ESI source (JEOL Co. Ltd., Tokyo, Japan). The separation column was a TSKgel ODS-100V column (250 mm × 2.0 mm; i.d.: 5 μm; Tosoh Corporation, Tokyo, Japan), and the mobile phases A and B were H~2~O/CH~3~CN (80:20) containing 0.1% AcOH, and CH~3~CN/H~2~O (80:20) containing 0.1% AcOH, respectively. High-pressure linear gradient elution of the mobile phases A and B was carried out in the following manner: B (%: 38.0--38.0--40.0--40.0), time (min: 0--5.0--7.0--40.0). The mobile phase was constantly pumped at 0.16 mL min^−1^, and the column temperature was maintained at 40 °C. The conditions for ESI-MS detection were as follows: negative ion mode; needle voltage set at −2,000 V; and the ring lens and orifice 1 and 2 voltages set at −10, −35, and −7 V, respectively. Nitrogen was used as the nebulizing and desolvation gas, and pressure was maintained constant at 0.608 MPa. The desolvation chamber and orifice 1 temperatures were set to 250 °C and 120 °C, respectively. Data were obtained using Mass Center software, MS-56010MP (JEOL).

Calibration and statistical analyses
------------------------------------

Two calibration curves were constructed using the peak area ratio of [l]{.smallcaps}-Trp or [l]{.smallcaps}-KYN to I.S. (50 or 2.5 μM), plotted against [l]{.smallcaps}-Trp (10--200 μM) or [l]{.smallcaps}-KYN (0.5--5.0 μM) concentration (n = 4). Using these calibration curves, [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in human serum were determined. Unpaired Student's *t*-tests were performed to assess the significance of differences between 2 groups. Association between 2 groups was evaluated by Pearson's correlation test. A *P*-value below 0.05 was considered significant.

Results and Discussion
======================

It is known that both IDO and TDO are key enzymes for Trp metabolism,[@b6-ijtr-suppl.1-2013-009] and that [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN levels can be used to assess IDO and TDO activities.[@b10-ijtr-suppl.1-2013-009] Therefore, to monitor IDO or TDO activity in vivo, determination of both [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in bio-samples is necessary.[@b10-ijtr-suppl.1-2013-009]

Previously, we had reported the development of a method using HPLC with fluorescence detection for the determination of [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN.[@b17-ijtr-suppl.1-2013-009] Our previous HPLC method utilized a pre-column derivatization with (*R*)-DBD-PyNCS, which bears a fluorescent benzofurazan moiety (2,1,3-benzoxadiazole), with relatively long excitation and emission wavelengths. Fluorescence at 565 nm that originated from (*R*)- DBD-PyNCS upon excitation at 440 nm was used for detection. The recovery and stability of the derivative with (*R*)-DBD-PyNCS were sufficient for routine analysis by HPLC.[@b17-ijtr-suppl.1-2013-009] Under our previous HPLC conditions, a small amount of endogenous [l]{.smallcaps}-KYN in human serum was detected at around 49 min, while [l]{.smallcaps}-Trp was clearly determined at around 53 min (data not shown). Using fluorescence detection, a relatively long elution time is generally needed for separating other interfering peaks. However, marked [l]{.smallcaps}-KYN peak broadening occurred due to the relatively long elution time, and, for this reason, precise determination of trace [l]{.smallcaps}-KYN was difficult under the previous HPLC method. In contrast, selective ion monitoring (SIM) by means of MS detection can afford a single peak of analyte without complete separation.

To date, several reports have described that the benzofurazan moiety mentioned above is useful not only for fluorescence, but also for MS detection.[@b19-ijtr-suppl.1-2013-009],[@b20-ijtr-suppl.1-2013-009] Therefore, here, we changed the detection system from a fluorescence to MS system, using a JMS-T100 LP AccuTOF LC-Plus equipped with an ESI source (JEOL Co. Ltd., Tokyo, Japan), as an alternative detection method. Optimum conditions for the ionization and detection of [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN standards derivatized with (*R*)-DBD-PyNCS, such as settings for needle voltage, the ring lens, and orifice 1 and 2 voltages, were carefully investigated. Moreover, we also optimized the mobile phase of the HPLC system. Consequently, the peaks of [l]{.smallcaps}-Trp, [l]{.smallcaps}-KYN, or I.S. (50 and 2.5 μM) in human serum samples could be clearly detected, as shown in [Figure 1A--D](#f1-ijtr-suppl.1-2013-009){ref-type="fig"}. The detected ions, m/z 556.14, 560.13, and 497.16 were used for SIM of [l]{.smallcaps}-Trp, [l]{.smallcaps}-KYN, and I.S., respectively. In human serum, an unknown peak appearing after elution of the [l]{.smallcaps}-KYN peak was detected in SIM chromatograms at m/z 560.13 ([Fig. 1C](#f1-ijtr-suppl.1-2013-009){ref-type="fig"}). The unknown peak may be an isotope ion peak of [l]{.smallcaps}-Trp derivatized with DBD-PyNCS, as the elution time of the unknown peak was consistent with that of [l]{.smallcaps}-Trp ([Fig. 1A and C](#f1-ijtr-suppl.1-2013-009){ref-type="fig"}). The mass difference between [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN derivatized with DBD-PyNCS (m/z 556.14 and 560.13, respectively) is approximately 4, further supporting the likelihood that this unknown peak is an isotope ion peak of [l]{.smallcaps}-Trp derivatized with DBD-PyNCS.

The calibration curves obtained for [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN were linear (r^2^ = 0.9985 and 0.9978, respectively) in the range of 10--200 μM (n = 4) and 0.5--5.0 μM (n = 4), respectively. Relative standard deviation values (RSD%) for [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN were in the range of 0.24%--2.05% and 1.91%--4.44%, respectively, indicating that the proposed HPLC method was effective for the determination of [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN in human serum.

Since (*R*)-DBD-PyNCS, used as the derivatization reagent, has a chiral carbon in its structure, it is possible to detect both enantiomers of Trp and KYN, namely not only the [l]{.smallcaps}-form, but also the [d]{.smallcaps}-form in the chromatogram.[@b17-ijtr-suppl.1-2013-009],[@b21-ijtr-suppl.1-2013-009] In the present study, however, neither endogenous [d]{.smallcaps}-Trp, nor [d]{.smallcaps}-KYN, was detected in human serum. The detection and quantification limits in this study were approximately 150 nM and 0.5 μM for Trp and KYN, respectively, and, therefore, a more sensitive MS detection system would be necessary in order to detect these [d]{.smallcaps}-forms in human serum.

[Table 1](#t1-ijtr-suppl_1-2013-009){ref-type="table"} shows serum [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations (mean ± S.E.) in male and female subjects as determined by the LC-MS method presented here. In the present study, a slight but significant gender difference was observed (*P* \< 0.05), namely, the [l]{.smallcaps}-Trp concentration in the sera of male subjects was higher than that of female subjects. This result was consistent with those of a previous paper, describing that serum [l]{.smallcaps}-Trp concentration in males was higher than that in females.[@b22-ijtr-suppl.1-2013-009] The ratio of [l]{.smallcaps}-KYN to [l]{.smallcaps}-Trp ([l]{.smallcaps}-KYN/[l]{.smallcaps}-Trp), which is a tryptophan breakdown index representing the sum activities of TDO and IDO,[@b10-ijtr-suppl.1-2013-009],[@b23-ijtr-suppl.1-2013-009] showed no gender difference.

[Figure 2](#f2-ijtr-suppl.1-2013-009){ref-type="fig"} shows a correlation plot between [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in human sera. As shown in [Figure 2A](#f2-ijtr-suppl.1-2013-009){ref-type="fig"}, a significant positive correlation was observed (r = 0.532, *P* \< 0.05), suggesting that IDO or TDO typically play a role in the decomposition of [l]{.smallcaps}-Trp in normal subjects. [Figure 2B and C](#f2-ijtr-suppl.1-2013-009){ref-type="fig"} show correlation plots between [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in sera of male and female subjects, respectively. A significant correlation was observed in male subjects (r = 0.847, *P* \< 0.01), but not in female subjects. It is unclear why this gender difference was observed, but the menstrual cycle may affect the serum [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in female subjects.

As shown in [Figure 3](#f3-ijtr-suppl.1-2013-009){ref-type="fig"}, a slight negative correlation of [l]{.smallcaps}-KYN with age was observed (r = −0.466, *P* \< 0.05), while no correlation of [l]{.smallcaps}-Trp with age was observed (data not shown). [Figure 3B and C](#f3-ijtr-suppl.1-2013-009){ref-type="fig"} show correlation plots between [l]{.smallcaps}-KYN concentrations and age in sera of male and female subjects, respectively. In both male and female subjects, significant correlations \[r = −0.928 (*P* \< 0.01) and r = −0.651 (*P* \< 0.05), respectively\] were observed. However, in the present study, the serum samples were obtained from individuals younger than 30-years-old, and therefore, investigation of older subjects would be required in order to evaluate the correlation between age and [l]{.smallcaps}-KYN or [l]{.smallcaps}-Trp.

Conclusions
===========

[l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in human serum were determined by the proposed LC-MS method after derivatization with (*R*)-DBD-PyNCS. Using the proposed method, [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations in human serum can be determined using only 10 μL of the serum. This method will be helpful for the in vivo estimation of TDO and IDO activities in the field of clinical research.
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###### 

Serum [l]{.smallcaps}-Trp and [l]{.smallcaps}-KYN concentrations and the ratio (mean ± S.E.) in male or female subjects determined by the proposed LC-MS method.

                                                      Total (n = 19)   Male (n = 8)   Female (n = 11)
  --------------------------------------------------- ---------------- -------------- --------------------------------------------------------------------
  [l]{.smallcaps}-Trp (μM)                            86.13 ± 4.12     95.65 ± 4.27   79.20 ± 3.34[\*](#tfn2-ijtr-suppl_1-2013-009){ref-type="table-fn"}
  [l]{.smallcaps}-KYN (μM)                            1.84 ± 0.15      2.08 ± 0.17    1.66 ± 0.13
  [l]{.smallcaps}-KYN/[l]{.smallcaps}-Trp (×10^−2^)   2.15 ± 0.17      2.12 ± 0.11    2.17 ± 0.21

**Note:**

*P* \< 0.05 versus male.
